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Abstract
Background: The comparability of gene expression data generated with different microarray platforms is still a
matter of concern. Here we address the performance and the overlap in the detection of differentially expressed
genes for five different microarray platforms in a challenging biological context where differences in gene
expression are few and subtle.
Results: Gene expression profiles in the hippocampus of five wild-type and five transgenic δC-doublecortin-like
kinase mice were evaluated with five microarray platforms: Applied Biosystems, Affymetrix, Agilent, Illumina,
LGTC home-spotted arrays. Using a fixed false discovery rate of 10% we detected surprising differences between
the number of differentially expressed genes per platform. Four genes were selected by ABI, 130 by Affymetrix,
3,051 by Agilent, 54 by Illumina, and 13 by LGTC. Two genes were found significantly differentially expressed by
all platforms and the four genes identified by the ABI platform were found by at least three other platforms.
Quantitative RT-PCR analysis confirmed 20 out of 28 of the genes detected by two or more platforms and 8 out
of 15 of the genes detected by Agilent only. We observed improved correlations between platforms when ranking
the genes based on the significance level than with a fixed statistical cut-off. We demonstrate significant overlap
in the affected gene sets identified by the different platforms, although biological processes were represented by
only partially overlapping sets of genes. Aberrances in GABA-ergic signalling in the transgenic mice were
consistently found by all platforms.
Conclusion: The different microarray platforms give partially complementary views on biological processes
affected. Our data indicate that when analyzing samples with only subtle differences in gene expression the use of
two different platforms might be more attractive than increasing the number of replicates. Commercial two-color
platforms seem to have higher power for finding differentially expressed genes between groups with small
differences in expression.
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Microarray technologies are now commonly used for
genome-wide surveying of gene expression. With the
availability of an increasing amount of data from different
studies, there is a growing need for comparison and com-
bination of datasets. This would be helpful to increase sta-
tistical power and to compare biological processes.
Comparisons across different studies are, however, com-
plicated by the use of different platforms. Over the past
years, many microarray platforms, based on different
technologies, have been developed by commercial and
academic institutions. How reliable and consistent the
results from different platforms are is still a matter of
debate [1-3]. Initially, platforms comparison studies were
mainly focused on comparison between commercial
chips (mainly Affymetrix) and in-house spotted microar-
rays [4-7]. In recent years, more comprehensive studies
were done, some of them reporting agreement between
platforms [8-13] and some of them not [14-20]. The larg-
est comparison was performed within an FDA-initiated
program for evaluation of the reproducibility, quality and
consistency of microarray platforms (MicroArray Quality
Control, MAQC). In general, a high agreement between
platforms was reported [21-25]. Our study is an extension
to previously published studies in several aspects: we
investigated the capabilities of five microarray platforms
with high technological diversity to identify differences in
gene expression in a challenging and highly controlled
biological condition, where the expected level of tran-
scriptional regulation was low, the number of differen-
tially expressed genes small, and the number of biological
replicates small, but realistic.
The biological question addressed was the finding of dif-
ferential gene expression in the hippocampus between
transgenic mice overexpressing a splice-variant of the dou-
blecortin-like kinase-1 gene, δC-doublecortin-like kinase
(DCLK)-short, which makes the kinase constitutively
active [26]. The DCLK gene has recently been implicated
in crucial aspects of embryonic cortical development by
controlling neurogenesis, neuronal migration and neuro-
nal vesicle transport [27-30]. DCLK-short is not expressed
during embryogenesis, is abundantly expressed in adult
limbic brain structures, particularly in the hippocampus
[26], and has mild kinase activity in vitro [26,31]. The bio-
logical function of DCLK-short expression in the adult
hippocampus is largely unknown and the transgenic mice
have subtle phenotypes with no obvious differences in
basal outcomes (Schenk et al, in preparation). Microarray-
based expression profiling of the hippocampus tissues
from δC-DCLK-short and controls should reveal the bio-
logical processes in which the gene is involved.
The main aim of this paper is to compare the performance
of different microarray platforms to detect differences in
gene expression in biologically related samples. The per-
formance of and the consistency between the microarray
platforms on the level of affected genes and gene sets are
reported here. The biological findings will be discussed in
more detail elsewhere (Schenk, in preparation).
Results
Experimental set-up
Gene expression in the hippocampus of five wild-type
mice and five transgenic mice was evaluated with five
microarray platforms (Table 1): Applied Biosystems
(ABI), Affymetrix (AFF), Agilent (AGL), Illumina (ILL),
and home-spotted oligonucleotide arrays (LGTC). Ten
chips were used for each platform. For the two-color
arrays, a wild-type sample was always co-hybridized with
a transgenic sample and the design was balanced with
respect to dye. Platform-specific processing of the signal
was kept to a minimum as to not introduce processing
artefacts. After careful performance evaluation, different
normalization methods were chosen for one and two-
color, but within the groups of one- and two-color plat-
forms the method was kept constant as not to introduce
differences due to the normalizaton algorithm. Differen-
tial gene expression was evaluated with an empirical Bayes
linear regression model (EBLRM) from the R package
limma [32]. Raw and normalized data are available from
Gene Expression Omnibus (GEO) under series GSE8349.
Detected transcripts
There was a large difference between the platforms in the
number of probes which generated a signal above back-
ground. AGL had the highest number of present calls,
LGTC the lowest. To make a fair comparison across plat-
forms, we re-annotated all probe sequences and mapped
them to the Ensembl transcript database. In addition to
providing the most up-to-date annotation, alternatively
spliced transcripts are considered separately so that possi-
ble inconsistencies between platforms due to measuring
different splice variants would be excluded. The number
of detectable Ensembl transcripts was high on AGL
(22,510), intermediate on AFF, ILL, and ABI (around
13,000) and low on LGTC (2,017) (Table 2). The low
number of detectable transcripts on the LGTC platform is
mainly due to background problems, causing negative
control spots to occasionally give high signals. The over-
lap between detectable transcripts is highest between AFF
and AGL (62%) and lowest for all LGTC combinations.
Differentially expressed genes identified on each platform
The number of significantly differentially expressed genes
(DEGs) detected with a fixed False Discovery Rate (FDR)
of 10% greatly varied across platforms (Table 1): 4 probes
were selected by ABI, 130 by AFF, 3,051 by AGL, 54 by ILL,
and 13 by LGTC. As expected, the observed degree of dif-
ferential gene expression was small. The absolute expres-Page 2 of 13
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1.45 – 2.23-fold (ABI), 1.10 – 2.58-fold (AFF), 1.05 –
2.40-fold (AGL), 1.15 – 1.92-fold (ILL), and 1.04 – 1.47-
fold (LGTC). The only two DEGs with a more than two-
fold change in expression (as found with multiple micro-
array platforms and confirmed by qPCR) were: Plac9 (up)
and Gabra2 (down).
We further investigated the surprisingly high number of
DEGs detected by AGL. When intensities instead of ratios
were taken into the statistical analysis, no differential
genes were detected at a FDR of 10% unless dye and array
effect were included in the model. With the latter model
(model 3 in the Methods section), 3,570 genes were
selected, among which all the 3,051 genes selected by the
log ratios-based analysis. This and the more elaborate
evaluation presented in Additional file 1 suggest three
major explanations for the good performance of the AGL
platform: co-hybridization of samples from the two differ-
ent biological groups to the same array, doubling of the
number of observations with the same number of arrays
used for the one-color systems, and low noise levels.
These conclusions are in accordance with observations
from earlier studies [13,33].
The low number of DEGs on the ABI platform may be
partly attributable to the use of different batches of arrays,
but including the batch effect in the statistical model did
not result in more DEGs.
Analysis of overlapping DEGs across platforms
To be able to compare results across platforms, we created
two data subsets with genes or transcripts interrogated by
all platforms. For the first subset all GenBank accessions
that were used by the array suppliers for their probe design
were mapped to Unigene (UG) database, while averaging
signal intensities from probes that mapped to the same
UG entry. For 10,876 UG IDs data was available for all 5
platforms. For the second subset, we mapped all probes to
the Ensembl transcript database. There were 12,774
Ensembl transcripts that were interrogated by all 5 plat-
forms.
Table 1: Description of the platforms under study.
Platform Name #Probes #Unique 
UniGene IDs
#Ensembl 
transcripts *
one/two
color
# DEGs
(10% FDR)
# DEGs 
UniGene 
dataset
(N = 10,876)
# DEGs 
Ensembl 
dataset
(N = 12,744)
ABI Applied Biosystem- 
AB1700
35,948 19,013 25,858 one 4 4 5
AFF Affymetrix – Mouse 
Genome 430 v2.0 Array
45,101 20,320 23,553 one 130 72 112
AGL Agilent- WMG G4122A 41,232 20,612 25,845 two 3,051 1,594 2,003
ILL Illumina- Sentrix Mouse- 
6 Expression BeadChip
46,133 19,292 25,629 one 54 19 24
LGTC Home-spotted 65-mer 
oligonucleotide arrays 
(Sigma- Compugen 
collection)
21,997 15,261 18,104 two 13 22 35
All 
Platforms
10,876 12,744 - 285** 693**
* More probes could correspond to the Ensembl transcript.
** The number of differential genes obtained comes from the integrated analysis of data from all platforms within one statistical model which takes 
the platform into account (cf. Discussion section)
Table 2: Overlap in detectable Ensembl transcripts across platforms. The number of detectable transcripts is presented on the 
diagonal (bold), with the total number of interrogated transcripts for each platform between parentheses. The overlap in the number 
of detectable transcripts for each pair of platforms is presented in the right side of the table, with the total number of interrogated 
transcripts shared between each pair of platforms between parentheses. The pair-wise overlap in detectable transcripts as a 
percentage of the overlapping set of interrogated Ensembl transcripts is presented in the left side of the table.
Detectable transcripts ABI AFF AGL ILL LGTC
ABI 13331 (22963) 8897 (15950) 11863 (20858) 9449 (21055) 1557 (15221)
AFF 55.8% 11683 (18572) 10986 (17698) 9226 (17645) 1487(13987)
AGL 56.9% 62.1% 22510 (26233) 12120 (23933) 1800 (17329)
ILL 44.9% 52.3% 50.6% 13376 (26550) 1617 (17225)
LGTC 10.2% 10.6% 10.4% 9.4% 2017 (18591)Page 3 of 13
(page number not for citation purposes)
BMC Genomics 2008, 9:124 http://www.biomedcentral.com/1471-2164/9/124Results for the subset of genes with overlapping UG iden-
tifiers are reported in Table 1 and show the same trend
already observed in the complete datasets. In Table 3 the
overlaps in DEGs selected by each pair of platforms are
reported. Two genes were selected by all 5 platforms
(Plac9, 9230117N10Rik). The 4 genes identified by ABI
were selected on at least three other platforms. Overall,
correspondence between platforms appears to be low.
This is likely due to the use of a fixed statistical threshold.
A higher correlation was found when evaluating the ranks
of genes based on significance score. In Figure 1 the ranks
for each gene are plotted for each pair of platforms. A scat-
tersmooth function [34] is used for better visualization of
the data cloud. As can be seen, in the area of the highly
ranked genes (roughly from rank 1 – rank 200) there is a
higher correlation between platforms than in the area of
lower ranked genes. This is expected because only genes
with significantly differential expression should be corre-
lated while no correlation and complete scattering is
expected for unchanged genes. We also considered the
moderate t-statistics from the EBLRM which takes into
account the direction of changes in the gene expression.
The Pearson correlation coefficients (cP) of the t statistics
within pair of platforms ranged between 0.10–0.47 (Table
3). Correlations between pairs of platforms belonging to
the same type (one- or two-color) where higher than
between those of different types, with cP = 0.47 between
AFF – ILL and between AGL – LGTC. Given the fact that
the correlations are calculated based on all genes of which
the biggest majority does not change in expression, higher
correlations are not to be expected.
The results of the analysis of the Ensembl transcript-
mapped overlapping probes were highly similar in terms
of overlap (Table 1), and correlations of ranks and t-statis-
tics (data not shown).
Validation
Quantitative reverse transcription PCR (qRT-PCR) was
used to validate the results of the different microarray
platforms [see Additional file 2]. As expected the two
genes found as DEGs by all five microarray platforms were
confirmed to display differential expression. The fold-
changes found by qRT-PCR were slightly higher than
those found by any of the microarray platforms, confirm-
ing previous observations that ratios tend to be com-
pressed in microarray experiments [21,23,35]. For 10 out
of 11 tested genes that were significant (FDR<0.1) on at
least two platforms, qRT-PCR experiments confirmed dif-
ferential expression (Student's t-test: p < 0.05). Lgals1, that
was found by AFF and ILL only, did not reach significance
in the qRT-PCR experiment due to large variability in the
wild-type group. We selected 15 genes (ranked from 8 to
719) that were found by AGL only covering the range
from highly to lowly expressed genes, to ascertain whether
the high number of genes selected by AGL was due to false
positives. Eight out of these 15 genes were confirmed by
qRT-PCR (p < 0.05), including Spp1 and Camkk1. These
two genes were ranked among the top-350 genes on all
platforms, except for Camkk1 on ABI. Pip5k2a, Ttc3, and
Acsl1 were confirmed by qRT-PCR, but had an average
ranking on the other platforms, and thus are truly found
by AGL only. Of the 7 genes that were found by AGL only
but could not be confirmed by qRT-PCR, Gnb1l and Sgip1
were border-line significant in the qRT-PCR experiment (p
= 0.06). Interestingly, Taf12, although significant on AGL
only, displayed very consistent fold-changes on the five
microarray platforms (-1.08 to -1.12). Probably its fold-
change was so low that it was hard to confirm by qRT-
PCR.
Gene set analysis
Analysis at the level of gene sets (as annotated in the Gene
Ontology -GO- [36] and Kyoto Encyclopedia of Genes
and Genomes -KEGG- [37] libraries) may reveal greater
similarities between platforms than analysis at the level of
individual genes, since different but functionally-related
genes could give hints to aberrations in the same biologi-
cal processes [38]. The Global Test was used to evaluate
the differential regulation of gene sets [39]. This method
is based on a model for predicting a response variable
from the gene expression measurements of a set of genes.
Unlike commonly overrepresentation test or Gene Set
Enrichtment Analysis, it has optimal power in small sam-
ple size experiments and is able to identify gene sets where
many genes display a small but consistent effect [40]. Fur-
thermore, the test enables the control for array and dye
effects, and produces easily interpretable p-values that can
be compared across experiments.
We ranked the gene sets based on their Global Test signif-
icance and compared each pair of platforms (Figure 2).
Like for the analysis of individual genes, the highly ranked
gene sets showed good agreement across platforms. Again,
the best correlations were observed between pairs of plat-
forms of the same type: AFF-ILL (both one-color) and
LGTC-AGL (both two-color) with Spearman correlation
coefficients of 0.39 and 0.46 respectively. In agreement
with the lower number of DEGs found by ABI, the results
Table 3: Overlap in DEGs in the UG subset (normal face) and 
Pearson correlation coefficients (bold face) between t statistics 
in each pair of platforms.
C(Pearson)\ # DEGs AFF ABI ILL AGL LGTC
AFF 72 4 12 25 4
ABI 0.26 4 3 4 3
ILL 0.47 0.22 19 10 3
AGL 0.18 0.16 0.17 1594 19
LGTC 0.11 0.10 0.11 0.47 22Page 4 of 13
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platforms. Similar results were observed using the gene
sets from KEGG (data not shown).
The list of gene sets that were consistently identified by at
least three platforms is dominated by genes involved in
GABAergic signaling (Table 4). Gabra2, found down-regu-
lated on all platforms and confirmed by qRT-PCR [see
Additional file 2], is the most influential gene in these
gene sets. Different genes on different platforms contrib-
ute to the significance of these gene sets as a whole: e.g.
Chrna4 (AFF, AGL, LGTC), Chrna3 (AGL), Glra3 (LGTC),
Glra4 (ILL) for gene set GO:0004890. In general, this was
due to near-background signals of these genes on most
platforms.
Discussion
The aims of the present study were to compare the ability
of different microarray platforms to detect differences in
gene expression, when levels of regulation and numbers
of regulated genes are low, and to investigate the influence
of the platform in the biological interpretation of the
results.
We show that even when gene expression differences
between groups are small, several microarray platforms
Scattersmooth plots of the correlation between the ranks (according to p values) of genes in the UG dataset of the 5 platformsFigure 1
Scattersmooth plots of the correlation between the ranks (according to p values) of genes in the UG dataset of the 5 plat-
forms. Red corresponds to denser areas, while yellow corresponds to non dense areas. The scattersmooth uses an algorithm 
for smoothing of two dimensional histograms with smoothed densities (26). This graph is more meaningful than a traditional 
scatter plot of the p values or of the -log p values, where the smallnumber of DEGs in our datasets originates graph blurred 
with thousands of overlapping dots and empty areas. Since the different signal to noise ratio is varying in the platforms and 
affects the statistics differently, plots of the ranks are more meaningful than plot of p values and statistics.
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BMC Genomics 2008, 9:124 http://www.biomedcentral.com/1471-2164/9/124are able to consistently detect them. This is an important
point, since in most previously published microarray plat-
form comparisons, including the toxicogenomics MAQC
study where biological replicates were analyzed, differ-
ences between samples analyzed where much larger than
in our study [12,21,23-25]. The MAQC papers conclude
that the cross-platform correlation is higher for fold-
changes than for t-statistics. This is not true for our study.
This apparent contradiction is because high fold-changes,
which we simply do not have in our study, are more likely
to be measured consistently, and contribute most to the
Pearson correlation coefficient. Cross platform consist-
ency in our study may compare favorably to another plat-
form comparison study within a biological setting: Tan et
al. reported a low agreement between 3 platforms
(Affymetrix, Agilent, Amersham) in the analysis of the
effect of serum withdrawal [14]. In their case, the amount
of interrogated genes shared by all platforms was low. In
our study, the number of common probes is bigger (N~
12,000) and allows for more reliable comparisons since a
bigger and possibly more representative set of probes is
taken into consideration.
In contrast to other papers, we did not apply any filter to
our data. In the reanalysis of the Tan dataset by Shi and
collaborators [41] the authors claimed that the use of the
unfiltered dataset gave a poor agreement between plat-
forms, while restricting the analyses to a small filtered
subset gives highly reproducible results. Even if several fil-
ters are commonly used, strict investigation on the possi-
ble bias introduced in the data because of the exclusion of
genes has not been done. Since filters of the data may
affect individual datasets differently, we have avoided
using them in order to reflect the true unbiased gene
Scattersmooth plots between the ranks of the GO gene sets (according to Global Test p values)Figure 2
Scattersmooth plots between the ranks of the GO gene sets (according to Global Test p values).
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measures are more affected by biological and technical
noise.
The choice of the type of cut-off is still a matter of debate,
and several authors suggested using a mixed cut-off of p-
values and Fold Changes (FCs) [21,24]. However, even if
a FC cut-off makes DEGs determination easier and from
the technical point of view is more direct, it can eliminate
the possibility of finding small differences in the data that
are biologically interesting, as demonstrated in the current
study (where only two genes showed a FC > 2). Further-
more, the FC statistics do not have the probabilistic char-
acteristics guaranteed by theoretical conditions that allow
to be sure about what the method does [42,43].
The degree of overlap between DEGs can be influenced by
the overlap in interrogated and detectable transcripts as
well as the method for matching of the probes. The over-
lap in interrogated transcripts was >75%, as expected for
these whole genome microarray platforms. The overlap in
probes with signal above background was also in the same
range. However, by adding the two effects, one can
explain as much as 50% of the difference between two
platforms and this can be even more for home-spotted
arrays were the numbers of detectable transcripts are often
reduced due to local background problems. The overlap
may be further reduced due to the interrogation of differ-
ent splice variants that are mapped to the same UG iden-
tifier. The Ensembl transcript mapping accounts for
alternatively spliced transcripts. However, the correlation
between platforms in the Ensembl transcript-mapped
dataset was, in our case, not higher than in the UG dataset.
This could be due to complications in the mapping proc-
ess: AFF probe sets sometimes cover more than one tran-
script, and for ABI oligonucleotide sequences were not
provided but only 380 bp regions in which the probes
were designed. Furthermore, there is considerable redun-
dancy in the Ensembl transcript dataset due to multiple
splice variants from the same gene being detected by all
platforms, which may introduce biases in the downstream
analyses. In this respect, the use of the recently released
whole genome exon arrays for gene expression probably
provides an attractive alternative, coping with such a
problem.
AGL selected a ten-fold higher number of DEGs and sig-
nificant gene sets than all other platforms. This is partly
attributable to the high signal to noise level of this plat-
form, as evident from the number of probes with signal
higher than background. Still, this huge difference was
unexpected and we investigated the behavior of the AGL
Table 4: Gene sets highly ranked across platforms. For each platform, gene sets were ranked by their association with the phenotype 
under study, using the p-value from the global test. Displayed are those gene sets that rank highly in the majority of platforms; for GO 
sets, the sum of the highest three (out of five) ranks had to be below 100; for KEGG sets, the sum of the highest four (out of five) ranks 
had to be below 100. Columns 1 and 2 display GO/KEGG IDs and names of the gene sets (in parentheses: GO classification: BP = 
biological process; MF = molecular function). Columns 3 to 7 display the ranks of the gene sets for each of the platforms.
GENE SET ID Name ABI AFF AGL ILL LGTC
GO
GO:0007214 gamma-aminobutyric acid signaling pathway (BP) 232 46 23 26 33
GO:0004890 GABA-A receptor activity (MF) 248 42 11 13 48
GO:0016917 GABA receptor activity (MF) 283 40 14 12 52
GO:0030594 neurotransmitter receptor activity (MF) 433 23 2 2 166
GO:0042165 neurotransmitter binding (MF) 474 22 1 1 174
GO:0006821 chloride transport (BP) 853 17 3 22 21
GO:0015698 inorganic anion transport (BP) 1022 7 21 33 76
GO:0005230 extracellular ligand-gated ion channel activity (MF) 1672 29 10 17 91
GO:0006820 anion transport (BP) 1801 8 33 34 98
GO:0015276 ligand-gated ion channel activity (MF) 1900 20 4 11 175
GO:0050900 leukocyte migration (BP) 13 898 12 69 1726
KEGG
4080 Neuroactive ligand-receptor interaction 25 1 3 2 10
4512 ECM-receptor interaction 18 9 21 16 33
2010 ABC transporters – General 27 3 15 4 53
4660 T cell receptor signaling pathway 23 16 57 8 31
760 Nicotinate and nicotinamide metabolism 58 8 4 161 20
3030 DNA polymerase 9 11 12 24 138
4514 Cell adhesion molecules (CAMs) 39 13 23 17 115
900 Terpenoid biosynthesis 13 12 54 19 62
4640 Hematopoietic cell lineage 64 4 22 9 76Page 7 of 13
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BMC Genomics 2008, 9:124 http://www.biomedcentral.com/1471-2164/9/124data in more detail, and compared this with AFF and
LGTC data using different approaches [see Additional file
1]. Briefly, the AGL log ratios show a bigger variability
than AFF log intensities, measured by the a posteriori
standard deviations. This difference remains after multi-
plying the variance of AFF intensities by the square root 2
in order to calculate the variance in the ratio between two
samples. To check whether the doubled number of obser-
vations on the AGL were the cause for finding many more
differentially expressed genes, we left AGL arrays out one
by one and repeated the EBLRM analysis. The number of
DEGs decreased steadily from 3,051 (10 arrays, 20 sam-
ples) to 649 (5 arrays, 10 samples). This is on the same
order of magnitude as the number of DEGs of AFF (10
arrays, 10 samples, 130 DEGs), but still five times larger.
This suggests that the direct comparison of the wild-type
and transgenic mouse samples on the same array drives
the better performance, which is accordance with previous
observations [13,33]. It argues against using either a com-
mon reference design or one-color protocols when com-
paring two groups of samples [21]. However, this does not
explain the differences in performance between AGL and
LGTC arrays. We found that AGL's technical replicates
were much more reproducible than those of LGTC: Pear-
son correlation coefficients were 0.95–0.98 for AGL and
0.70–0.80 for LGTC, illustrating the differences in quality
between commercial and home-spotted arrays. Overall,
our study suggests that the differences in amount of DEGs
found by the different platforms were mainly caused by
differences in signal to noise ratios, and the numbers of
observations between one and two-color platforms, when
using the same number of arrays. Our qRT-PCR experi-
ments validated differential gene expression in most cases,
also for genes found by AGL only, indicating that these are
not just false positives.
Our results illustrates once more that typical sample sizes
used in microarray experiments, three samples per group,
can be too small to enable reliable detection of subtle
effects such as in this study. Even though using 5 samples
per group still does not yield enough power for some plat-
forms, it is possible to use our data as basis for estimation
of sample size for the platforms considered. We are under-
going this work and the detailed analysis, beyond the
scope of this paper, shall appear elsewhere. Our prelimi-
nary results confirm that AGL and AFF have comparable
power, so the different outcomes observed by us are for
the largest part due to the larger effective sample size
involved in two-colour platforms design.
We investigated whether the power of the analysis could
be enhanced by merging data from all five platforms in
one statistical model. We applied an EBLRM on the UG
subset and included samples, platforms and dye (only for
the two-color arrays) as confounders. At an FDR of 0.1,
285 genes were selected (Table 1). Among these, most had
been selected as DEGs by the individual platforms with
the exception of 56 genes. However, we could not validate
the differential expression of the top 5 of those genes by
qRT-PCR, mainly due to large biological variation within
groups. These genes seem to have been selected in the
merged analysis due to the technical consistency on the
microarray platforms allied to the larger pooled sample
size.
This study also aims to elucidate the biological function of
delta-DCLK-short expression in the hippocampus. Recent
loss and gain of function studies strongly suggest involve-
ment of the DCLK gene in neurogenesis, neuronal migra-
tion, vesicle transport, microtubule-directed retrograde
transport, neurotransmission and apoptosis [28-30,44-
46]. Thus, DEGs identified in this study may be involved
in these processes. The present study focuses on compari-
son of different array platforms and therefore the results
of the biological function will be discussed more exten-
sively elsewhere (Schenk in preparation). However, it is
interesting to note that the DEGs and the significant gene
sets revealed by the different microarrays are biologically
meaningful. For example, numerous gene sets related to
GABA-ergic neurotransmission emerged as highly signifi-
cant in 4 out of 5 platforms. Intriguingly, similarly as the
DCLK gene, excitatory GABA signalling has been shown to
control neurogenesis, neuronal migration and differentia-
tion of neuroblasts [47,48]. DCLK-short expression starts
postnatally around day 6, a timepoint that is characterized
by a switch in excitatory GABAergic responses to inhibi-
tory responses [49,50]. The added value of the use of dif-
ferent microarray platforms lies in the prioritization of the
pathways for follow-up experiments. When analyzing
data from a single platform, many spurious gene sets
apparently not related to the biological process under
study (e.g. chemotaxis) ranked highly, probably due to
the relatively small expression differences observed. By
comparing platforms, a biologically meaningful consen-
sus could be distilled.
Conclusion
The present study suggests that the choice of a platform
can be mainly governed by practical and cost considera-
tions. However, our data demonstrate that, given the
much higher number of identified DEGs, commercial
two-color platforms may be preferred when two groups
with small differences in expression are to be compared.
In these situations, a direct-comparison design helps to
maximize signal-to-noise ratios in the ratios between the
two groups through minimization of the array effect and
the possibility for more replicates with the same number
of arrays. Since we performed this study with a clear
underlying biological question, we could demonstratePage 8 of 13
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turbed biological processes identified. Consistency
between platforms helped to prioritize biological proc-
esses relevant for the biological question under study. The
relevant gene sets were detected with an only partly over-
lapping set of genes. Our data indicate that when analyz-
ing samples with only subtle differences in gene
expression the use of two different platforms might be
more rewarding than increasing the number of replicates
on the same platform.
Methods
MICE
5 Wild-type male C57/BL6j and 5 transgenic male mice
over-expressing DCLK-short with a C57/BL6j background
were individually housed 7 days prior to the start of the
experiment. Animals were housed under standard condi-
tions, 12h/12h light/dark cycle and had access to food
and water ad libitum. Wild-type (N = 5) and transgenic (N
= 5) tissue samples were collected by taking the brain
from the skull and quickly dissecting out both hippoc-
ampi. Dissection was performed at 0°C to prevent degra-
dation of RNA. Hippocampi were put directly in pre-
chilled tubes containing Trizol reagent (Invitrogen Life
Technologies, Carlsbad, CA, USA). All animal treatments
were approved by the Leiden University Animal Care and
Use Committee (UDEC# 01022).
RNA extraction
After transfer to ice-cold Trizol, hippocampi were homog-
enized using a tissue homogenizer (Salm&Kipp, Breuke-
len, The Netherlands) and total RNA was isolated
according to the manufacturer's protocol. After precipita-
tion, RNA was purified with Qiagen's RNeasy kit with on-
column DNase digestion. The quality of the RNA was
assessed with the RNA 6000 Labchip kit in combination
with the Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA, USA), using the Eukaryote Total RNA Nano
assay according to the manufacturer's instructions. Total
RNA was amplified using Ambion's MessageAmp kit, with
incorporation of modified nucleotides (biotin-16-UTP
(AFF, ILL), aminoallyl-UTP (AGL, LGTC), DIG-UTP
(ABI)). For AGL and LGTC, aminoallyl-cRNA was coupled
to Cy3 or Cy5 monoreactive dyes (GE Healthcare).
Experimental design
Labelled cRNAs of 5 individual wild-type and 5 transgenic
mice were hybridized on 5 different microarray platforms
(Table 1): Applied Biosystem (ABI), Affymetrix (AFF), Agi-
lent (AGL), Illumina (ILL), and home-spotted glass
microarrays containing the 22K mouse Sigma-Compugen
collection generated at the Leiden Genome Technology
Center (LGTC). Ten microarrays were used for each plat-
form. For the one-color platforms (ABI, AFF, ILL), each
individual RNA was hybridized to one microarray. A
direct design was used for hybridization of the two-color
arrays (AGL, LGTC), i.e. each microarray was hybridized
with two RNA samples from different groups. All samples
were hybridized once in Cy3 and once in Cy5. Dye-
swapped hybridizations were done with non-identical
sample pairs [see Additional file 3].
Quantitative RT-PCR
Quantitative RT-PCRs were done on the Lightcycler480
(Roche), using the universal probe library (UPL, Roche)
or SYBR-Green (when amplification efficiencies with UPL
were below 90%). The RNA samples used for validation
were the same as in the microarray experiments. Each
cDNA was analyzed in quadruplicate, after which the
average threshold cycle (Ct) was calculated per sample.
Differential expression was evaluated with a Student's t-
test, considering the 5 biological replicates in each group.
Mapping
Two approaches were used to obtain an overlapping gene
set that was measured on each platform. The first is based
on the annotation provided by the manufacturer, while
the second is an in-house performed probe sequence-
based annotation.
1. GenBank accession numbers that were used for the
design of the microarray probes were used for querying
the Mus musculus Unigene (UG) database build #151. All
UG IDs that occurred at least once on each platform were
included in the UG set (N = 10,876). With this UG set, a
UG dataset was created for each platform by extracting the
expression values for the relevant probes. When multiple
probes were present for the same UG ID, the average of
the signal of the probes was used as expression value.
2. For AGL, LGTC, and ILL, probe sequences provided by
the manufacturer were directly used for annotation. For
AFF, the 11 probe sequences in a probe set were concate-
nated, after removal of potential overlap. ABI did not
reveal the exact probe sequences but a 380 bp region, in
which the probes were located. Gmap [51] was used for
alignment of the sequences to the Ensembl mouse
genome sequence (build NCBIM34). Hits with a match
score higher than 0.9 (matches – gaps/query size [52])
were considered genuine matches. Chromosomal start
and end positions of the hits were compared to the exon
positions in the Ensembl database (version 37.34e). Sub-
sequently, the Ensembl Transcript database was queried
with only the exons that matched (part of) the probe
sequence. Only transcripts with a match score >0.9 on all
5 platforms were included the Ensembl transcript set (N =
12,744). When multiple probes were present for the same
transcript, the average of the signal of the probes was used
as expression value.Page 9 of 13
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set was created for each platform, which was analyzed sep-
arately [for UG: see Additional file 4]. For completeness,
the complete datasets (including also the non overlapping
probes) were also analyzed in parallel.
Preprocessing procedures
The quality of the arrays was assessed by visual inspection
of the raw images and pairwise MA-plots. No arrays were
excluded from the analysis since the variance on the log-
ratios was comparable between arrays. For the ABI plat-
form, we observed differences in the signal distribution
between two batches of arrays hybridized on two different
days, for the other platform no quality problems were
observed. Each dataset was loaded into the R environment
directly as a raw data matrix (for ABI and ILL) or using the
limma package (AFF, AGL, and LGTC). No background
correction was applied to the two-color microarray plat-
forms since the background correction increased noise
levels in the low intensity range considerably. For AFF
analysis, only perfect match probes were taken into
account and probesets were summarized with the
"median polish" method. The data from the one-color
platforms were normalized with variance stabilization
and normalization function implemented in the vsn pack-
age [53]. From all the normalization methods tested, vsn
was most robust, whereas the performance of alternative
normalization algorithms was more platform-dependent.
Two-color arrays were normalized with loess [54] since
vsn normalization did not correct all the intensity-
dependent non-linear behaviour in the data. Raw and
normalized data are available in GEO under series
GSE8349.
Present calls
For Affymetrix chips, probes were said to be present when
the MAS5.0 present call algorithm called the probe "P"
(present) on all 10 arrays. For the other platforms, probes
were said to be present when their signal intensity was
above the signal from the lowest 95% of platform-specific
negative control probes on all 10 arrays. For the two col-
our platforms, this requirement was imposed on the
intensities of both the green and the red channel. Lists of
present probes for each platform were then mapped to the
ENSEMBL transcript database to generate a list of unique
ENSEMBL transcript IDs with detectable expression.
Statistical analyses
Determination of Differentially Expressed Genes (DEGs)
Each dataset was analyzed for determination of DEGs
using an Empirical Bayes Linear Regression Model
(EBLRM). The following models were used for this pur-
pose:
1) one-color datasets
yi = αi + βi group + εi
2) two-color datasets- log ratios
wi = αi + εi
3) two-color datasets-intensities
yi = αi + βi group + γi dye + δi array + εi
where i is the ith item of the datasets, yi is the intensity sig-
nal, wi is the log ratios of the signal in Cy3 dye vs the Cy5
dye; αi, βi, γi, δi, εi were the coefficients of the intercept,
group (transgenic vs. wild type), dye (Cy5 vs. Cy3 – only
for two-color arrays), array (only for two-color arrays),
and error terms, respectively. All the effects were consid-
ered to be random. DEGs were defined as the probes for
which the βi were significantly different from 0, since βi is
the estimate for the group (wild-type or transgenic) effect.
Analysis were performed with the limma package [32],
using the lmFit function. P values were adjusted for mul-
tiple testing using the False Discovery Rates (FDR)
method suggested by Benjamini and Hochberg [55]. FDR
not greater than 10% was considered as statistically signif-
icant. Numbers and percentages of overlapping items in
the list of DEGs among the 5 platforms were calculated.
Genes of UG and Ensembl were ordered by their p values
obtained from the EBLRM and their Spearman correlation
coefficients (cS) were calculated for pairs of platforms.
Pearson correlation coefficients (cP) were calculated to
quantify the correlation between the statistics produced
by the EBLRM in the 5 overlapping datasets.
Gene set analysis
The association between the multiple functionally-related
genes belonging to the same gene sets (according to the
GO [36] and KEGG [37] libraries) and the group was
assessed using the Global Test [39]. A logistic model with
a gamma p-value estimating method was used for all plat-
forms. For the two-color arrays, intensities were extracted
and a model including array and dye effects as confound-
ers was used. Gene sets were ordered by their p values
obtained from the global test and Spearman correlation
coefficients were calculated for pairs of platforms. Multi-
ple testing was corrected via the FDR method [55]. FDR
not greater than 10% was considered as statistically signif-
icant.
Two-color platforms data analysis
Analyses of the two-color platforms data were done using
log ratios per array, whenever possible. However, for the
gene set analysis and for the analysis of the merged data-
sets separate channel intensities were needed. These were
then extracted from the raw data, normalized using vsnPage 10 of 13
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model also included array and dye as confounders.
Software
All the analyses were performed using R software environ-
ment [56] version 2.3.2 and BioConductor [57] packages
vsn [53], loess [54], multtest [58], Affy [59], globaltest
[39], limma [32], AnnBuilder [60] and the function scat-
tersmooth [34].
When metadata packages were available at the BioCon-
ductor website (in our case, for AGL and AFF platforms),
we used them for the annotation. Otherwise (for ABI, ILL,
and LGTC) the annotation packages were produced using
the AnnBuilder package in R [60].
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